Profitability
Weight: 25%
C
52
- 5yr Avg ROIC 4.3%
- Operating Margin Trend +35.83 pp/yr
BCRX
BioCryst Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Share-Count CAGR 5.5%
Growth Quality
Weight: 25%
A+
100
- 5yr Revenue CAGR 117.9%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
D+
43
- 5yr FCF Margin -31.2%
- 5yr FCF/NI Conversion 1.24x
Balance Sheet
Weight: 10%
B
71
- Net Debt / EBITDA 0.47x
- Interest Coverage (EBIT/Int) 4.39x
- Altman Z-Score 2.26
Stability
Weight: 5%
A
88
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 7
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 2 added; 2 trimmed.
- Holders
- 4 +1
- Avg Δ position
- -12.6%
- New buys
- 0
- Full exits
- 0
- Greenblatt decreased -50%
- Cooperman increased +35%
- Dalio decreased -23%